HEB - Hemispherx Biopharma, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.2330
+0.0072 (+3.19%)
As of 10:13AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2258
Open0.2600
Bid0.2289 x 900
Ask0.2400 x 800
Day's Range0.2289 - 0.2553
52 Week Range0.1500 - 0.6500
Volume255,081
Avg. Volume243,953
Market Cap11.009M
Beta-0.01
PE Ratio (TTM)N/A
EPS (TTM)-0.2340
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.52
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe

    Hemispherx Biopharma, Inc. (NYSE American:  HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen® (rintatolimod), which is slated for multiple uses including product launch in Argentina, where Ampligen is approved for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), ME/CFS expanded access program (EAP) in the United States and Europe and an EAP in the Netherlands for pancreatic cancer. Ampligen, a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, was approved for commercial sale in Argentina in 2016 for the treatment of ME/CFS, the first therapy ever approved for this quality-of-life impacting disease.

  • GlobeNewswire23 days ago

    Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order

    Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released  for patients' use in the pancreatic cancer Early Access Program (EAP) in the Netherlands pursuant to the terms of our agreement with our EAP provider. This is the initial shipment (500 vials) of a previously announced 2,100 vial standing stock order issued by myTomorrows, our EAP provider in Europe (https://globenewswire.com/news-release/2016/05/23/842404/0/en/Hemispherx-Amends-and-Restates-Agreement-with-myTomorrows-for-the-Early-Access-Program-for-Rintatolimod-in-Europe.html;  https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/form10-k.htm). Early Access Programs, also known as Expanded Access Programs, are market-specific regulatory programs whereby certain governments allow companies to make a drug available with reimbursement approved before it is officially commercialized for serious or life-threatening diseases outside of a clinical trial — if certain criteria are met — with potential benefits both for patients and for drug development.

  • GlobeNewswire27 days ago

    Hemispherx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    ORLANDO, Fla., Aug. 24, 2018-- Hemispherx Biopharma, Inc. an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it will be presenting ...

  • GlobeNewswirelast month

    Hemispherx Reports Six Months Ended June 30, 2018 Financial Results and Provides Business Update

    Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, has announced its financial results for the six months ended June 30, 2018. The Company has made great progress pursuing Ampligen in combination therapeutic treatments in immuno-oncology. Significant synergistic anti-tumor activity and/or increased median survival has been observed when Ampligen was added to other anti-cancer agents in three pre-clinical studies.

  • GlobeNewswirelast month

    Hemispherx Updates Stockholders, Highlighting Ampligen’s Role in Enhancing Immunotherapeutic Therapies

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, is pleased to announce it mailed a letter to stockholders on August 11, 2018 detailing recent developments, including financial results and new business opportunities. A strategic decision to prioritize Ampligen’s potential in combination therapeutic treatments in immuno-oncology.

  • ACCESSWIRE2 months ago

    Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: HEB, HTBX, and PBYI LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . On Friday, benchmark US ...

  • GlobeNewswire2 months ago

    Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine

    Hemispherx Biopharma, Inc. (NYSE American:HEB) announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen® in combination with FluMist® influenza vaccine with the U.S. Food and Drug Administration. Hemispherx is a research and development and, consistent with its commercial and early access program approvals, an emerging commercial development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. The two-stage randomized, double-blinded, placebo-controlled, clinical trial assessed the immunogenicity and safety of intranasal FluMist administered sequentially with intranasal Ampligen.

  • GlobeNewswire3 months ago

    Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies

    Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D company focused on unmet medical needs in immunology, is pleased to enthusiastically support National Immunization Awareness Month (NIAM), which is observed annually during August. NIAM is designed “to celebrate the benefits of vaccination and highlight the importance of vaccination for people of all ages,” according to its sponsor, the National Public Health Information Coalition. To learn more about NIAM, please click here.

  • ACCESSWIRE3 months ago

    Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.

  • GlobeNewswire3 months ago

    Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

    Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the immediate expansion of its Treatment Protocol/Expanded Access Programs for ME/CFS in the United States, known as AMP-511, to new enrollees for the first time in more than a year. This opportunity to expand the scope of AMP-511 is based on the successful completion of the first phase of its Ampligen manufacturing initiative producing sufficient quantities of Ampligen to support new enrollees in this FDA-approved program. Additional enrollees will be added as supplies of Ampligen expand with the successful fill and finish of additional commercial-sized lots similar to the 8,500 vials just released for human use.

  • How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?
    Simply Wall St.4 months ago

    How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?

    After reading Hemispherx Biopharma Inc’s (AMEX:HEB) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).

  • ACCESSWIRE5 months ago

    Wired News – ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World

    Stock Monitor: Hemispherx Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If ...